Latest news
FDA feedback supports new testing path for therapy in MS relapses - Multiple Sclerosis News TodayMultiple Sclerosis News Today · Thu, 06 Aug 2026 22:51:52 GMTOculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses - Quiver QuantitativeQuiver Quantitative · Mon, 03 Aug 2026 08:10:00 GMTFDA Says Oculis Can Cross-Reference Data for Planned MS Relapse Trial - Stock TitanStock Titan · Mon, 03 Aug 2026 08:00:00 GMTOculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Yahoo Finance UKYahoo Finance UK · Mon, 03 Aug 2026 08:00:00 GMT